Obinutuzumab Infusion-Related Reactions: Multicenter Retrospective Evaluation of Incidence, Severity, and Risk Factors
Journal of the Advanced Practitioner in Oncology · 01.11.2024 · 15 (7) · 437-443
DOI: 10.6004/jadpro.2024.15.7.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Advanced Practitioner in Oncology, online erschienen am 01.11.2021. Verfasst von Erin Hickey Zacholski und 4 weiteren Autor:innen. Beteiligte Einrichtung: From Virginia Commonwealth University School of Pharmacy, Richmond, Virginia. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Despite standard prevention strategies, obinutuzumab carries a significant risk of infusion-related reactions (IRRs) for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Reported rates of IRRs vary in phase III clinical trials evaluating obinutuzumab-containing regimens. Although obinutuzumab has a higher rate of severe (grade 3 and higher) IRRs than rituximab, clinical risk factors predicting IRR have not been identified, and therefore strata informing patient-specific risk of IRR have not been applied in practice.
Methods
This multicenter, retrospective evaluation of patients with CLL/SLL estimated the incidence of obinutuzumab-related IRRs and evaluated risk factors for the development of IRR in a real-world population.
Results
68 patients with untreated or previously treated CLL/SLL were included in the analysis, with the majority being older adult (median age = 70) males (61.8%) with Rai stage III and IV CLL. All-grade IRRs occurred in 25% of patients, and severe IRRs occurred in 1.5% of patients. Of the variables evaluated, absolute lymphocyte count was a significant predictor (p ≤ .05) of the odds of experiencing an IRR in patients receiving obinutuzumab.
Conclusion
Obinutuzumab IRR rates in a real-world population were comparable to most phase III clinical trial results succeeding implementation of split dosing and standard premedication. Absolute lymphocyte count is a statistically significant predictor for increased odds of experiencing an IRR. Future research evaluating risk-adapted obinutuzumab administration strategies is needed to recommend a specific approach.
Autor:innen und Institutionen
- From Virginia Commonwealth University School of Pharmacy, Richmond, Virginia.
- Virginia Commonwealth University Health, Richmond, Virginia.
- Atrium Health Levine Cancer Institute, Charlotte, North Carolina.
Zitieren
APA
Zacholski, E. H., Rugh, S., Marshall, J., Nadpara, P., & Moore, D. (2024). Obinutuzumab Infusion-Related Reactions: Multicenter Retrospective Evaluation of Incidence, Severity, and Risk Factors. Journal of the Advanced Practitioner in Oncology, 15(7), 437-443. https://doi.org/10.6004/jadpro.2024.15.7.2
Vancouver
Zacholski EH, Rugh S, Marshall J, Nadpara P, Moore D. Obinutuzumab Infusion-Related Reactions: Multicenter Retrospective Evaluation of Incidence, Severity, and Risk Factors. Journal of the Advanced Practitioner in Oncology. 2024;15(7):437-443. doi:10.6004/jadpro.2024.15.7.2
BibTeX
@article{Zacholski2024,
author = {Zacholski, Erin Hickey and Rugh, Sarah and Marshall, Jenna and Nadpara, Pramit and Moore, Donald},
title = {Obinutuzumab Infusion-Related Reactions: Multicenter Retrospective Evaluation of Incidence, Severity, and Risk Factors},
journal = {Journal of the Advanced Practitioner in Oncology},
year = {2024},
volume = {15},
number = {7},
pages = {437--443},
doi = {10.6004/jadpro.2024.15.7.2}
}
EUVIMED